The portable ATUSA™ System reportedly provides 3D ultrasound visualization of the entire breast volume in two minutes.
A new modality that may redefine the efficiency of breast imaging has received 510(k) clearance from the Food and Drug Administration (FDA). The new ATUSA™ System, a portable whole breast ultrasound device, can provide 3D imaging in two minutes, according to iSono Health, the manufacturer of the device.
Featuring intuitive software designed to integrate with machine learning models, the ATUSA system provides efficient automated scans of breast volume and analysis. Emphasizing patient comfort, the ultrasound device also offers a compact portability with a unique wearable accessory.
“A portable and automated whole breast ultrasound augmented with machine learning would be the most practical technology to reduce breast cancer mortality globally, specifically in countries with limited resources. In developed countries, ultrasound has proven effective as an adjunct to mammography to improve breast cancer diagnosis in women with dense breasts,” noted Mohammad Eghtedari, M.D., Ph.D., a breast radiologist and assistant professor at the University of California-San Diego. “I believe iSono Health’s automated and portable technology will improve access to breast care for women worldwide and empower physicians with insightful data to make more informed clinical decisions.
The ATUSA system also facilitates consistent, reproducible accuracy, regardless of the experience level of the physician, Maryam Ziaei, Ph.D., the co-founder and CEO of iSonoHealth
“Clinicians and women worldwide need high quality breast imaging that is accessible and efficient at scale without the need for highly skilled operators,” emphasized Maryam Ziaei, Ph.D, the co-founder and CEO of iSonoHealth. “The portable and automated ATUSA system stands alone in comparison to other ultrasound offerings in promising to address that need.”
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.